• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SYMATESE EVOLYSSE SMOOTH; IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SYMATESE EVOLYSSE SMOOTH; IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Catalog Number EVO-SMTH-01
Medical Device Problem Code Off-Label Use (1494)
Health Effect - Clinical Codes Hypersensitivity/Allergic reaction (1907); Burning Sensation (2146); Swelling/ Edema (4577)
Date of Event 11/10/2025
Type of Reportable Event Serious Injury
Event or Problem Description
On (b)(6) 2025, a healthcare professional injected 1cc of evolysse smooth into a patient's lips.On (b)(6) 2025, the patient received injections of tirzepatide and vitamin b3, after which they experienced swelling at the injection site, as well as lip swelling and tingling.That same day, the healthcare provider referred the patient to the emergency room (er), where treatment included intravenous epinephrine and steroids, followed by a 10-day course of oral steroids.On (b)(6) 2025, the final day of oral steroids, the patient again had swollen lips.The patient visited their primary care provider (pcp) on (b)(6) 2025, was prescribed oral steroids, and referred to an allergist.The patient's lip swelling subsided once oral steroids were re-started.
 
Additional Manufacturer Narrative
The filler was injected into the patient and is not available for return.Inflammatory responses, such as swelling or erythema, can develop near sites of dermal filler injection following viral or bacterial illnesses, vaccinations, or dental interventions.In certain instances, adverse effects may present weeks, months, or even years after the procedure; this is a recognized potential adverse event as stated in the product labeling.In this case, the product was administered off-label to the lip region.The reaction occurred soon after the administration of tirzepatide and vitamin b3.Consequently, we cannnot rule out that this may be possible causation of the reaction.Complaints: (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVOLYSSE SMOOTH
Common Device Name
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
SYMATESE
zi les troques
chapnost, auvergne-rhone-alpes 69630
FR  69630
Manufacturer (Section G)
SYMATESE
zi les troques
chapnost, auvergne-rhone-alpes 69630
FR   69630
Manufacturer Contact
laurence hermitte
zi les troques
chapnost, auvergne-rhone-alpes 69630
FR   69630
MDR Report Key23789359
Report Number3003672980-2025-00171
Device Sequence Number18759556
Product Code LMH
UDI-Device Identifier03760172161271
UDI-Public(01)03760172161271(17)270331(10)S2251530008
Combination Product (Y/N)Y
Initial Reporter StateKS
Initial Reporter CountryUS
PMA/510(K) Number
P240022
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2025
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional,Distributor
Initial Reporter Occupation Nurse Practitioner
Type of Report Initial
Report Date (Section B) 12/12/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberEVO-SMTH-01
Device Lot NumberS2251530008
Was Device Available for Evaluation? No
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 11/24/2025
Initial Report FDA Received Date12/12/2025
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured04/24/2025
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
TIRZEPATIDE; VITAMIN B3 INJECTION
Outcome Attributed to Adverse Event Other;
Patient SexFemale
-
-